Citi raised the firm’s price target on Edwards Lifesciences (EW) to $96 from $95 and keeps a Buy rating on the shares. The company reported a Q3 beat with an increased revenue outlook, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $99 from $95 at Barclays
- Edwards Lifesciences Reports Strong Q3 2025 Growth
- Closing Bell Movers: Amazon soars to all-time highs on earnings
- Edwards Lifesciences Announces CFO Transition Plan
- Edwards Lifesciences CFO Ullem to transition from role by mid-2026